204 related articles for article (PubMed ID: 14660622)
1. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.
Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC
J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622
[TBL] [Abstract][Full Text] [Related]
2. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.
Walker JB; Bajzar L
J Biol Chem; 2004 Jul; 279(27):27896-904. PubMed ID: 15128744
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
4. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
[TBL] [Abstract][Full Text] [Related]
5. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.
Schneider M; Boffa M; Stewart R; Rahman M; Koschinsky M; Nesheim M
J Biol Chem; 2002 Jan; 277(2):1021-30. PubMed ID: 11684677
[TBL] [Abstract][Full Text] [Related]
6. Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor.
Marx PF; Havik SR; Bouma BN; Meijers JC
J Thromb Haemost; 2005 Jun; 3(6):1293-300. PubMed ID: 15946220
[TBL] [Abstract][Full Text] [Related]
7. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
Boffa MB; Wang W; Bajzar L; Nesheim ME
J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.
Ceresa E; De Maeyer M; Jonckheer A; Peeters M; Engelborghs Y; Declerck PJ; Gils A
J Thromb Haemost; 2007 Oct; 5(10):2105-12. PubMed ID: 17666015
[TBL] [Abstract][Full Text] [Related]
9. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
Plug T; Marquart JA; Marx PF; Meijers JC
J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360
[TBL] [Abstract][Full Text] [Related]
10. Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation.
Schneider M; Nagashima M; Knappe S; Zhao L; Morser J; Nesheim M
J Biol Chem; 2002 Mar; 277(12):9944-51. PubMed ID: 11786552
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
[TBL] [Abstract][Full Text] [Related]
12. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
Bouma BN; Meijers JC
J Thromb Haemost; 2003 Jul; 1(7):1566-74. PubMed ID: 12871292
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage.
Marx PF; Hackeng TM; Dawson PE; Griffin JH; Meijers JC; Bouma BN
J Biol Chem; 2000 Apr; 275(17):12410-5. PubMed ID: 10777524
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity.
Zhao L; Buckman B; Seto M; Morser J; Nagashima M
J Biol Chem; 2003 Aug; 278(34):32359-66. PubMed ID: 12799375
[TBL] [Abstract][Full Text] [Related]
15. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Bazzi ZA; Lanoue D; El-Youssef M; Romagnuolo R; Tubman J; Cavallo-Medved D; Porter LA; Boffa MB
BMC Cancer; 2016 May; 16():328. PubMed ID: 27221823
[TBL] [Abstract][Full Text] [Related]
16. The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.
Wu C; Kim PY; Manuel R; Seto M; Whitlow M; Nagashima M; Morser J; Gils A; Declerck P; Nesheim ME
J Biol Chem; 2009 Mar; 284(11):7059-67. PubMed ID: 19074424
[TBL] [Abstract][Full Text] [Related]
17. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.
Zhou X; Declerck PJ
J Thromb Haemost; 2015 Jun; 13(6):1084-9. PubMed ID: 25773535
[TBL] [Abstract][Full Text] [Related]
18. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
Schneider M; Nesheim M
J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
[TBL] [Abstract][Full Text] [Related]
19. Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
Foley JH; Kim PY; Mutch NJ; Gils A
J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134
[TBL] [Abstract][Full Text] [Related]
20. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor.
Wang W; Boffa MB; Bajzar L; Walker JB; Nesheim ME
J Biol Chem; 1998 Oct; 273(42):27176-81. PubMed ID: 9765237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
